Drug Profile
Serlopitant - VYNE Therapeutics
Alternative Names: JTS 661; MK-0594; VPD-737Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Japan Tobacco; Menlo Therapeutics; Merck & Co; Torii Pharmaceutical
- Class Antipruritics; Antitussives; Cyclopentanes; Isoindoles; Skin disorder therapies; Small molecules; Urologics
- Mechanism of Action Neurokinin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alcoholism; Cough; Overactive bladder; Pruritus
Most Recent Events
- 24 Jun 2022 Stanford University, Epidermolysis Bullosa Research Partnership and Menlo Therapeutics completes a phase II trial in Pruritus (In adolescents, In adults, In the elderly) in USA (PO, Tablet) (NCT03836001)
- 08 Sep 2020 Menlo Therapeutics is now called VYNE Therapeutics
- 17 Jun 2020 Menlo Therapeutics terminates a phase III trial in Pruritus (associated with prurigo nodularis, atopic dermatitis, or psoriasis) in USA, Austria, Germany, Poland (PO) (NCT03540160)